108 related articles for article (PubMed ID: 3693587)
21. Usefulness of estimating individual pharmacokinetic data for aminoglycoside therapy in seriously ill patients.
Denaro CP; Ravenscroft PJ
Aust N Z J Med; 1987 Oct; 17(5):526-32. PubMed ID: 3446165
[TBL] [Abstract][Full Text] [Related]
22. Aminoglycoside forecasting in neutropenic patients with cancer.
Kosirog JL; Rospond RM; Destache C; Hall P
Clin Pharmacokinet; 1993 Jan; 24(1):79-87. PubMed ID: 8448975
[TBL] [Abstract][Full Text] [Related]
23. Bayesian Forecasting for Intravenous Tobramycin Dosing in Adults With Cystic Fibrosis Using One Versus Two Serum Concentrations in a Dosing Interval.
Drennan PG; Thoma Y; Barry L; Matthey J; Sivam S; van Hal SJ
Ther Drug Monit; 2021 Aug; 43(4):505-511. PubMed ID: 33941739
[TBL] [Abstract][Full Text] [Related]
24. [Individualized monitoring of the therapy with gentamycin using pharmacokinetic methods. Which method to choose?].
Carvalho A; Fonseca C; Falcão F; Pereira TA; Freitas O; Parrinha A; Costa M; Rodrigues MJ; Ceia F; Luís AS
Acta Med Port; 1996; 9(7-9):187-95. PubMed ID: 9005695
[TBL] [Abstract][Full Text] [Related]
25. Tobramycin dosing in mechanically ventilated patients. Inaccuracy of a 'rule of thumb'.
Martin C; Mallet MN; Saux P; Bruguerolle B; Herat V; Gouin F
J Antimicrob Chemother; 1988 Oct; 22(4):505-11. PubMed ID: 3204077
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of a two-compartment Bayesian feedback program for therapeutic tobramycin monitoring in the daily clinical use and comparison with a non-Bayesian one-compartment model.
Kaufmann GR; Vozeh S; Wenk M; Haefeli WE
Ther Drug Monit; 1998 Apr; 20(2):172-80. PubMed ID: 9558131
[TBL] [Abstract][Full Text] [Related]
27. Tobramycin population pharmacokinetics in neonates.
de Hoog M; Schoemaker RC; Mouton JW; van den Anker JN
Clin Pharmacol Ther; 1997 Oct; 62(4):392-9. PubMed ID: 9357390
[TBL] [Abstract][Full Text] [Related]
28. Suboptimal aminoglycoside dosing in critically ill patients.
Rea RS; Capitano B; Bies R; Bigos KL; Smith R; Lee H
Ther Drug Monit; 2008 Dec; 30(6):674-81. PubMed ID: 19057371
[TBL] [Abstract][Full Text] [Related]
29. An updated comparison of drug dosing methods. Part III: Aminoglycoside antibiotics.
Erdman SM; Rodvold KA; Pryka RD
Clin Pharmacokinet; 1991 May; 20(5):374-88. PubMed ID: 1908755
[TBL] [Abstract][Full Text] [Related]
30. Tobramycin-furosemide interaction.
Kaka JS; Lyman C; Kilarski DJ
Drug Intell Clin Pharm; 1984 Mar; 18(3):235-8. PubMed ID: 6697885
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of a Bayesian method for predicting vancomycin dosing.
Burton ME; Gentle DL; Vasko MR
DICP; 1989 Apr; 23(4):294-300. PubMed ID: 2728513
[TBL] [Abstract][Full Text] [Related]
32. Comparison of two Bayesian approaches to dose-individualization for once-daily aminoglycoside regimens.
Duffull SB; Kirkpatrick CM; Begg EJ
Br J Clin Pharmacol; 1997 Feb; 43(2):125-35. PubMed ID: 9131944
[TBL] [Abstract][Full Text] [Related]
33. Two-point method for determination of aminoglycoside pharmacokinetics: theoretical and practical considerations.
Hamilton RA; Chow MS
Ther Drug Monit; 1986; 8(3):274-8. PubMed ID: 3750369
[TBL] [Abstract][Full Text] [Related]
34. Comparing 3 methods of monitoring gentamicin concentrations in patients with febrile neutropenia.
Avent ML; Teoh J; Lees J; Eckert KA; Kirkpatrick CM
Ther Drug Monit; 2011 Oct; 33(5):592-601. PubMed ID: 21912332
[TBL] [Abstract][Full Text] [Related]
35. Comparison of a Bayesian program with three microcomputer programs for predicting gentamicin concentrations.
Godley PJ; Black JT; Frohna PA; Garrelts JC
Ther Drug Monit; 1988; 10(3):287-91. PubMed ID: 3176104
[TBL] [Abstract][Full Text] [Related]
36. Reliability of mini-bronchoalveolar lavage for the measurement of epithelial lining fluid concentrations of tobramycin in critically ill patients.
Boselli E; Breilh D; Djabarouti S; Guillaume C; Rimmelé T; Gordien JB; Xuereb F; Saux MC; Allaouchiche B
Intensive Care Med; 2007 Sep; 33(9):1519-23. PubMed ID: 17530217
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations.
Coulthard KP; Peckham DG; Conway SP; Smith CA; Bell J; Turnidge J
J Cyst Fibros; 2007 Apr; 6(2):125-30. PubMed ID: 16829216
[TBL] [Abstract][Full Text] [Related]
38. A prospective study evaluating tobramycin pharmacokinetics and optimal once daily dosing in burn patients.
Lee C; Walker SAN; Walker SE; Seto W; Simor A; Jeschke M
Burns; 2017 Dec; 43(8):1766-1774. PubMed ID: 28647460
[TBL] [Abstract][Full Text] [Related]
39. [Pharmacokinetic monitoring during aminoglycoside treatment: the optimal method for individualizing the dosage of tobramycin].
Firsov AA; Manuĭlov KK; Fomina IP; Lukomskiĭ GI; Alekseeva ME
Antibiot Khimioter; 1989 Dec; 34(12):915-20. PubMed ID: 2629652
[TBL] [Abstract][Full Text] [Related]
40. Systematically individualizing tobramycin dosage regimens.
Cipolle RJ; Seifert RD; Zaske DE; Strate RG
J Clin Pharmacol; 1980 Oct; 20(10):570-80. PubMed ID: 7440765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
